Bioequivalence of LB80380 Free Base and Maleate Salt Tablets
An Open-label, Phase I Study in Healthy Male Subjects to Compare the Pharmacokinetics of LB80331 and LB80317, Metabolites of LB80380, After a Single Oral Administration of LB80380 Free Base 150 mg (60 mg + 90 mg) Tablet or LB80380 Maleate Tablet 183 mg (150 mg as a Free Base)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Clinical Trial Center, Samsung Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male with good health
- 20 to 45 years of age at screening
- Body weight ±20% of ideal body weight
- Willingness and ability to comply with study procedures and communicate with investigators
- Provided written consent voluntarily after informed of all the pertinent aspects of the trial
Exclusion Criteria:
- Clinically significant abnormality on medical interview, physical examination, electrocardiogram or clinical laboratory evaluations
- Clinically significant acute or chronic medical conditions
- Use of prescriptive medicine within 14 days, or over-the-counter drug within 7 days before the first day of drug administration
- Participation in clinical trial within 3 months before the first day of drug administration
- Alcohol abuse
- Habitual smoker
- Habitual user of herbal medicine
- Use of grapefruit-containing food or grapefruit juice during the study period
- Positive drug abuse test and Positive HBs-antigen, HCV-antibody, or HIV-antibody test
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: LB80380 maleat salt
|
183 mg (150 mg as a free base)
|
|
Active Comparator: LB80380 free base
|
150 mg
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
AUC
Time Frame: up to 144 hours
|
up to 144 hours
|
|
Cmax
Time Frame: up to 144 hours
|
up to 144 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants with Adverse Events and Number of Adverse Events as a Measure of Safety and tolerability
Time Frame: up to 7 days
|
up to 7 days
|
|
|
Profile of Pharmacokinetics
Time Frame: up to 144 hours
|
Tmax, Aet, CL/F
|
up to 144 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Wooseong Huh, Prof, Samsung Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- LG-BVCL009
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.